# Efficacy and Safety of Four Doses of Cenerimod Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus

> **NCT03742037** · PHASE2 · COMPLETED · sponsor: **Viatris Innovation GmbH** · enrollment: 427 (actual)

## Conditions studied

- Systemic Lupus Erythematosus

## Interventions

- **DRUG:** Cenerimod 0.5 mg
- **DRUG:** Cenerimod 1 mg
- **DRUG:** Cenerimod 2 mg
- **DRUG:** Cenerimod 4 mg
- **DRUG:** Placebo
- **DRUG:** cenerimod 2 mg (ex-4 mg)

## Key facts

- **NCT ID:** NCT03742037
- **Lead sponsor:** Viatris Innovation GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-12-21
- **Primary completion:** 2021-08-31
- **Final completion:** 2022-08-25
- **Target enrollment:** 427 (ACTUAL)
- **Last updated:** 2025-10-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03742037

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03742037, "Efficacy and Safety of Four Doses of Cenerimod Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT03742037. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*